TipRanks
BioNTech SE (MX:BNTXN)
:BNTXN
Mexico Market
BNTXN
BioNTech SE
RESEARCH TOOLSreports

BioNTech SE (BNTXN) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

BNTXN Analyst Ratings

Moderate Buy
15Ratings
Moderate Buy
11 Buy
4 Hold
0 Sell
Based on 15 analysts giving stock ratings to
BioNTech
SE
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BNTXN Stock 12 Month Forecast

Average Price Target

$2,311.92
▲(17.96% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for BioNTech SE in the last 3 months. The average price target is $2,311.92 with a high forecast of $2,630.15 and a low forecast of $1,631.82. The average price target represents a 17.96% change from the last price of $1,960.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1589":"$1,589","2110":"$2,110","2631":"$2,631","1849.5":"$1,849.5","2370.5":"$2,370.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2630.1452212,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.63K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2311.924487651343,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.31K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1631.8172422388,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.63K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1589,1849.5,2110,2370.5,2631],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1645.6,1721.3342477846154,1797.0684955692307,1872.8027433538462,1948.5369911384614,2024.271238923077,2100.0054867076924,2175.7397344923074,2251.473982276923,2327.2082300615384,2402.942477846154,2478.6767256307694,2554.4109734153844,{"y":2630.1452212,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1645.6,1696.855729819334,1748.111459638668,1799.3671894580023,1850.6229192773362,1901.8786490966704,1953.1343789160044,2004.3901087353386,2055.6458385546725,2106.9015683740067,2158.157298193341,2209.4130280126747,2260.668757832009,{"y":2311.924487651343,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1645.6,1644.539787864523,1643.479575729046,1642.4193635935692,1641.3591514580921,1640.2989393226153,1639.2387271871385,1638.1785150516614,1637.1183029161846,1636.0580907807077,1634.9978786452307,1633.9376665097539,1632.8774543742768,{"y":1631.8172422388,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1879,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1950,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1800,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1645,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1999,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1866.35,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1600.8,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1735,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1633,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1590,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1590,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1960,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1645.6,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$2,630Average Price Target$2,312Lowest Price Target$1,632
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on MX:BNTXN
Geoff Meacham
Citi
Citi
$2,348.34
Buy
19.81%
Upside
Reiterated
10/27/26
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (NYSE MKT: CATX), Incyte (NASDAQ: INCY) and BioNTech SE (NASDAQ: BNTX)
J.P. Morgan Analyst forecast on MX:BNTXN
Jessica Fye
J.P. Morgan
J.P. Morgan
$1,631.82
Hold
-16.74%
Downside
Reiterated
10/27/26
J.P. Morgan Sticks to Their Hold Rating for BioNTech SE (BNTX)
Bank of America Securities Analyst forecast on MX:BNTXN
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$2,141.69
Buy
9.27%
Upside
Reiterated
10/27/26
BioNTech: Advancing Oncology Pipeline and Promising Pumitamig Data Support Buy Rating; Price Target Reiterated at $114
Canaccord Genuity Analyst forecast on MX:BNTXN
John Newman
Canaccord Genuity
Canaccord Genuity
$2,479.85
Buy
26.52%
Upside
Reiterated
10/27/26
BioNTech SE (BNTX) Receives a Buy from Canaccord Genuity
Morgan Stanley Analyst forecast on MX:BNTXN
Terence Flynn
Morgan Stanley
Morgan Stanley
$2,141.69
Buy
9.27%
Upside
Assigned
10/26/26
BioNTech SE (BNTX) Receives a Buy from Morgan Stanley
UBS Analyst forecast on MX:BNTXN
David Dai
UBS
UBS
$2,536.21
Buy
29.40%
Upside
Reiterated
10/26/26
UBS Remains a Buy on BioNTech SE (BNTX)
Evercore ISI Analyst forecast on MX:BNTXN
Cory Kasimov
Evercore ISI
Evercore ISI
$2,442.28
Buy
24.61%
Upside
Reiterated
10/13/26
BioNTech: Outperform Rating Reaffirmed as Diversified Oncology Pipeline Offsets BNT113 Setback; $130 Price Target Maintained
Goldman Sachs Analyst forecast on MX:BNTXN
Asad Haider
Goldman Sachs
Goldman Sachs
$2,385.92
Buy
21.73%
Upside
Reiterated
10/13/26
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NYSE: NVO), Arcus Biosciences (NYSE: RCUS) and BioNTech SE (NASDAQ: BNTX)
BMO Capital Analyst forecast on MX:BNTXN
Evan Seigerman
BMO Capital
BMO Capital
$1,972.61
Hold
0.64%
Upside
Reiterated
10/12/26
BMO Capital Reaffirms Their Hold Rating on BioNTech SE (BNTX)
Argus Research Analyst forecast on MX:BNTXN
John Eade
Argus Research
Argus Research
―
Hold
―
Initiated
10/07/26
BioNTech initiated with a Hold at ArgusBioNTech initiated with a Hold at Argus
Berenberg Bank Analyst forecast on MX:BNTXN
Harry Gillis
Berenberg Bank
Berenberg Bank
$2,630.15
Buy
34.19%
Upside
Reiterated
10/07/26
Analysts Offer Insights on Healthcare Companies: BioNTech SE (NASDAQ: BNTX), Labcorp Holdings (NYSE: LH) and Surgery Partners (NASDAQ: SGRY)
Bernstein Analyst forecast on MX:BNTXN
Jeffrey Walch
Bernstein
Bernstein
$1,803.53
Hold
-7.98%
Downside
Reiterated
09/25/26
Analysts Conflicted on These Healthcare Names: Harmony Biosciences Holdings (NASDAQ: HRMY), BioNTech SE (NASDAQ: BNTX) and Biogen (NASDAQ: BIIB)
Wells Fargo Analyst forecast on MX:BNTXN
Mohit Bansal
Wells Fargo
Wells Fargo
$2,630.15
Buy
34.19%
Upside
Reiterated
09/24/26
Wells Fargo Remains a Buy on BioNTech SE (BNTX)
Jefferies Analyst forecast on MX:BNTXN
Akash Tewari
Jefferies
Jefferies
$2,592.57
Buy
32.27%
Upside
Reiterated
09/15/26
Jefferies Remains a Buy on BioNTech SE (BNTX)
Deutsche Bank Analyst forecast on MX:BNTXN
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
$2,630.15
Buy
34.19%
Upside
Reiterated
08/26/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on MX:BNTXN
Geoff Meacham
Citi
Citi
$2,348.34
Buy
19.81%
Upside
Reiterated
10/27/26
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (NYSE MKT: CATX), Incyte (NASDAQ: INCY) and BioNTech SE (NASDAQ: BNTX)
J.P. Morgan Analyst forecast on MX:BNTXN
Jessica Fye
J.P. Morgan
J.P. Morgan
$1,631.82
Hold
-16.74%
Downside
Reiterated
10/27/26
J.P. Morgan Sticks to Their Hold Rating for BioNTech SE (BNTX)
Bank of America Securities Analyst forecast on MX:BNTXN
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$2,141.69
Buy
9.27%
Upside
Reiterated
10/27/26
BioNTech: Advancing Oncology Pipeline and Promising Pumitamig Data Support Buy Rating; Price Target Reiterated at $114
Canaccord Genuity Analyst forecast on MX:BNTXN
John Newman
Canaccord Genuity
Canaccord Genuity
$2,479.85
Buy
26.52%
Upside
Reiterated
10/27/26
BioNTech SE (BNTX) Receives a Buy from Canaccord Genuity
Morgan Stanley Analyst forecast on MX:BNTXN
Terence Flynn
Morgan Stanley
Morgan Stanley
$2,141.69
Buy
9.27%
Upside
Assigned
10/26/26
BioNTech SE (BNTX) Receives a Buy from Morgan Stanley
UBS Analyst forecast on MX:BNTXN
David Dai
UBS
UBS
$2,536.21
Buy
29.40%
Upside
Reiterated
10/26/26
UBS Remains a Buy on BioNTech SE (BNTX)
Evercore ISI Analyst forecast on MX:BNTXN
Cory Kasimov
Evercore ISI
Evercore ISI
$2,442.28
Buy
24.61%
Upside
Reiterated
10/13/26
BioNTech: Outperform Rating Reaffirmed as Diversified Oncology Pipeline Offsets BNT113 Setback; $130 Price Target Maintained
Goldman Sachs Analyst forecast on MX:BNTXN
Asad Haider
Goldman Sachs
Goldman Sachs
$2,385.92
Buy
21.73%
Upside
Reiterated
10/13/26
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NYSE: NVO), Arcus Biosciences (NYSE: RCUS) and BioNTech SE (NASDAQ: BNTX)
BMO Capital Analyst forecast on MX:BNTXN
Evan Seigerman
BMO Capital
BMO Capital
$1,972.61
Hold
0.64%
Upside
Reiterated
10/12/26
BMO Capital Reaffirms Their Hold Rating on BioNTech SE (BNTX)
Argus Research Analyst forecast on MX:BNTXN
John Eade
Argus Research
Argus Research
―
Hold
―
Initiated
10/07/26
BioNTech initiated with a Hold at ArgusBioNTech initiated with a Hold at Argus
Berenberg Bank Analyst forecast on MX:BNTXN
Harry Gillis
Berenberg Bank
Berenberg Bank
$2,630.15
Buy
34.19%
Upside
Reiterated
10/07/26
Analysts Offer Insights on Healthcare Companies: BioNTech SE (NASDAQ: BNTX), Labcorp Holdings (NYSE: LH) and Surgery Partners (NASDAQ: SGRY)
Bernstein Analyst forecast on MX:BNTXN
Jeffrey Walch
Bernstein
Bernstein
$1,803.53
Hold
-7.98%
Downside
Reiterated
09/25/26
Analysts Conflicted on These Healthcare Names: Harmony Biosciences Holdings (NASDAQ: HRMY), BioNTech SE (NASDAQ: BNTX) and Biogen (NASDAQ: BIIB)
Wells Fargo Analyst forecast on MX:BNTXN
Mohit Bansal
Wells Fargo
Wells Fargo
$2,630.15
Buy
34.19%
Upside
Reiterated
09/24/26
Wells Fargo Remains a Buy on BioNTech SE (BNTX)
Jefferies Analyst forecast on MX:BNTXN
Akash Tewari
Jefferies
Jefferies
$2,592.57
Buy
32.27%
Upside
Reiterated
09/15/26
Jefferies Remains a Buy on BioNTech SE (BNTX)
Deutsche Bank Analyst forecast on MX:BNTXN
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
$2,630.15
Buy
34.19%
Upside
Reiterated
08/26/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AORTArtivion
MDWDMediwound
IMUXImmunic
RZLTRezolute
DFTXDefinium Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioNTech SE

3 Months
Akash TewariJefferies
Success Rate
9/15 ratings generated profit
60%
Average Return
+3.72%
Copying Akash Tewari's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +3.72% per trade.
1 Year
Robert BurnsH.C. Wainwright
Success Rate
11/22 ratings generated profit
50%
Average Return
+1.72%
Copying Robert Burns's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +1.72% per trade.
2 Years
Robert BurnsH.C. Wainwright
Success Rate
9/22 ratings generated profit
41%
Average Return
-3.63%
Copying Robert Burns's trades and holding each position for 2 Years would result in 40.91% of your transactions generating a profit, with an average return of -3.63% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BNTXN Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
9
8
6
4
5
Buy
12
10
21
33
48
Hold
6
5
5
6
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
27
23
32
43
62
In the current month, BNTXN has received 53 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. BNTXN average Analyst price target in the past 3 months is 2,311.92.
Each month's total comprises the sum of three months' worth of ratings.

BNTXN Financial Forecast

BNTXN Earnings Forecast

Next quarter’s earnings estimate for BNTXN is $14.06 with a range of -$0.42 to $28.52. The previous quarter’s EPS was -$68.21. BNTXN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BNTXN has Performed in-line its overall industry.
Next quarter’s earnings estimate for BNTXN is $14.06 with a range of -$0.42 to $28.52. The previous quarter’s EPS was -$68.21. BNTXN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BNTXN has Performed in-line its overall industry.

BNTXN Sales Forecast

Next quarter’s sales forecast for BNTXN is $21.74B with a range of $17.87B to $23.37B. The previous quarter’s sales results were $2.31B. BNTXN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BNTXN has Performed in-line its overall industry.
Next quarter’s sales forecast for BNTXN is $21.74B with a range of $17.87B to $23.37B. The previous quarter’s sales results were $2.31B. BNTXN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BNTXN has Performed in-line its overall industry.

BNTXN Stock Forecast FAQ

What is MX:BNTXN’s average 12-month price target, according to analysts?
Based on analyst ratings, BioNTech SE’s 12-month average price target is 2,311.92.
    What is MX:BNTXN’s upside potential, based on the analysts’ average price target?
    BioNTech SE has 17.96% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BioNTech SE a Buy, Sell or Hold?
          BioNTech SE has a consensus rating of Moderate Buy, which is based on 11 buy ratings, 4 hold ratings and 0 sell ratings.
            What is BioNTech SE’s share price target?
            The average share price target for BioNTech SE is 2,311.92. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $2,630.15 ,and the lowest forecast is $1,631.82. The average share price target represents 17.96% Increase from the current price of $1,960.
              What do analysts say about BioNTech SE?
              BioNTech SE’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of BioNTech SE?
                To buy shares of MX:BNTXN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.